Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dawn Muhlestein

Physician Assistant, Surgical Bountiful, UT Physician Assistant

NPI 1629374582 CMS profile 10434642

1551 Renaissance Towne Dr, Suite 400, Bountiful, UT 84010

Open in the dashboard

General payments

$1,708

70 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dawn Muhlestein of Bountiful, UT is reported in the CMS Open Payments database as having received $1,708 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $437 16
2024 General $420 18
2023 General $238 10
2022 General $343 16
2021 General $271 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dawn Muhlestein
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Dawn Muhlestein were reported at $437. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Dawn Muhlestein Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $271 $111 $36–$285 $132
2022 $343 $126 $44–$350 $149
2023 $238 $137 $47–$355 $160
2024 $420 $146 $49–$384 $164
2025 $437 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. 180 Medical, Inc. $338 10 payments
  2. Boston Scientific Corporation $167 4 payments
  3. AbbVie, Inc. $158 9 payments
  4. Astellas Pharma US Inc $133 6 payments
  5. Teleflex LLC $105 5 payments
  6. Rochester Medical Corporation $95 4 payments
  7. Sumitomo Pharma America, Inc. $92 4 payments
  8. ConvaTec Inc. $85 3 payments
  9. Coloplast Corp $59 3 payments
  10. Urovant Sciences Inc $44 2 payments
  11. Other $431 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,643 69 payments
  2. Education $65 1 payment
Products named General payments · program years 2021–2025
  1. GEMTESA $136 6 payments
  2. BOTOX $86 5 payments
  3. LUPRON DEPOT $73 4 payments
  4. GENTLECATH $71 2 payments
  5. Obtryx System - Curved $60 2 payments
  6. Lumenis Pulse 120H $58 1 payment
  7. UROLIFT $56 3 payments
  8. MYRBETRIQ $55 4 payments
  9. LithoVue $48 1 payment
  10. PROLARIS $41 1 payment
  11. Other $542 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,893

Median for Physician Assistant: 241

Drug cost

$266,410

Median for Physician Assistant: $4,110

Branded share of claims

34.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 189 $148,530
Gemtesa Vibegron Brand 55 $55,016
Mirabegron Er Mirabegron Brand 19 $11,382
Solifenacin Succinate Generic 234 $9,144
Methenamine Hippurate Generic 245 $7,241
Trospium Chloride Er Trospium Chloride Brand 39 $6,765
Estradiol Generic 97 $6,054
Trospium Chloride Generic 107 $5,612
Trimethoprim Generic 57 $5,492
Cefuroxime Cefuroxime Axetil Brand 183 $2,526

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$77,592

Of which drugs: $673

Medicare patients

430

Average age 75

Services billed

10,301

313 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 49%
Depression 41%
Chronic kidney disease 36%
Diabetes 35%
Osteoporosis 27%
Ischemic heart disease 20%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 18 2,225 $223
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 15 71 $145

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $57
$57 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $24
$24 55 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $19
$19 — —
MYRBETRIQ
  • Astellas Pharma US Inc $16
$16 189 —
Veozah
  • Astellas Pharma US Inc $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record